

Our Mission
3R Pharma is a pre-clinical stage company developing novel cannabidiol (CBD API)-based ocular therapies to replace/reduce the use of topical ocular steroids as the first line of treatment for chronic ocular surface diseases (MGD, Blepharitis). Our first drug product is an ophthalmic ointment targeting Meibomitis (MGD/Blepharitis Posterior).





Our Focus
Cronic ocular surface diseases, including Dry Eye, Blepharitis, and MGD, affect approximately 10% of the global population, significantly impacting comfort and quality of life. These conditions are among the primary reasons for visits to eye care professionals, leading to symptoms such as blurred vision, redness, chronic pain, burning sensations, and irritation. Current treatments involve a combination of corticosteroids antibiotics (like Tobradex and Maxitrol), which are effective but limited by serious side effects, such as cataract formation and increased ocular pressure, necessitating their short-term use. Despite the chronic nature of Dry Eye, there is a lack of long-term effective treatments, highlighting the urgent need for new therapies that provide lasting relief without harmful side effects. The global market for Dry Disease is expected to reach $8.21 billion by 2030.

Who We Are
Led by a team of industry experts
3R Pharma LTD is focused on creating advanced cannabinoid-based therapies aimed at treating chronic eye diseases for patients globally. We have collaborated with CanNegev Incubator, Padagis, BOL Pharma, OurCrowd, and the Israeli Innovation Authority, receiving pre-seed funding from the Israeli Innovation Authority to kickstart our research initiatives.
Our Partners
We have partnered with CanNegev Incubator that was established as a joint venture of Perrigo/Padagis, BOL Pharma, OurCrowd, and Israeli Innovation Authority, and received seed funding from the Israeli Innovation Authority to initiate our research.



